According to the study authors, bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) may be an option for simplification following viral suppression.
Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) maintained HIV viral suppression in adults with prior virological failures and with the K65N/R mutation, according to a study published in the International Journal of Infectious Diseases.
According to the authors, this study shows BIC/FTC/TAF may be an option for simplification following viral suppression.
The retrospective study included 72 people living with HIV (PLWH) 20 years and older with emergent K65N/R mutation who experienced previous virologic failures.
All participants received HIV care across 10 designated hospitals around Taiwan between November 1, 2019, and June 30, 2022. All participants were male, and the mode of HIV transmission was predominantly male-to-male sexual contact (91.6%).
Participants were eligible to switch to BIC/FTC/TAF after having achieved plasma HIV RNA load (PVL) less than 200 copies/mL for at least 3 months and were excluded if integrase inhibitor resistance-associated mutations were detected.
Of the 72 PLWH identified, 42 (59.7%) had concurrent M184V/I and 9 (12.5%) had at least 1 thymidine analogue mutation. The median (IQR) duration of HIV viral suppression was 4.7 (2.3-5.8) years. Most (97.2%) had PVL less than 50 copies/mL before switching.
After a median (IQR) observation of 98.6 (77.9-120.3) weeks, 68 (94.4%) participants continued BIC/FTC/TAF.
At week 48, the authors found the rate of losing virologic control was 2.8%, with only 2 participants experiencing this primary end point. Additionally, M184V/I was not associated with viral rebound.
Additionally, most (87.5%) PLWH in the study maintained virological suppression at week 48, and the incidence of viral rebound to more than 200 copies/mL was low at 2.2 per 100 person-years during the study period.
Limitations of the study include its single-arm retrospective observational design, lack of HIV RNA assessments at uniform time points, and some discontinuation due to the COVID-19 pandemic.
The authors also did not have data on PLWH who were eligible to switch but did not, nor did they have the resistance testing results of those experiencing viral rebound.
Additionally, these results may not be generalizable to PLWH who are not adherent to antiretroviral therapy.
Despite these limitations, the authors concluded this study demonstrated that BIC/FTC/TAF was effective in maintaining viral suppression for PLWH with K65N/R mutation.
“Given the good tolerability, low toxicity, reduced pill burden and high genetic barrier to resistance, BIC/FTC/TAF could be a therapeutic option for second-line treatment simplification,” they said.
Reference
Tsai MS, Sun HY, Chen CP, et al. Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation. Int J Infect Dis. Published online November 13, 2022. doi:10.1016/j.ijid.2022.11.012
Incidence Rate of Tuberculosis Among Individuals With HIV in Africa Higher Than Estimated
September 19th 2023The World Health Organization 2022 Africa regional report underestimated the incidence rate of tuberculosis in sub-Saharan African individuals living with HIV, according to a recent analysis.
Read More
Community Outreach Is Enabling CeSHHAR to Close HIV Care Gaps in Zimbabwe
April 6th 2021The Centre for Sexual Health and HIV/AIDS Research Zimbabwe conducts evidence-based research related to HIV and AIDS, as well as provides and implements sexual and reproductive health education and interventions among sex workers, children, and adolescents, and in the area of masculinity.
Listen
Differentiated Service Delivery Models Have Comparable Effectiveness to Standard of Care in HIV
September 6th 2023Patients with HIV were able to maintain care and achieve viral suppression with differentiated service delivery models with comparable effectiveness to the standard of care.
Read More
2 Clarke Drive
Cranbury, NJ 08512